首页> 外文OA文献 >PCN219 Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma

【2h】

PCN219 Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma

机译：PCN219 Prefmab：对先前未治疗的Cd20 +弥漫性大B细胞淋巴瘤或滤泡性淋巴瘤的皮下注射与静脉注射利妥昔单抗的患者满意度的最终分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rummel M; Kim TM; Plenteda C; Capochiani E; Mendoza M; Smith R; Osborne S; Grigg A;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20_ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab) [J] . Rummel M., Kim T. M., Aversa F., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第4期

机译：未处理的CD20_患者中皮下或静脉内施用Rituximab的偏好弥漫性大B细胞淋巴瘤或滤泡淋巴瘤：从前瞻性，随机，开放标签，交叉研究（PREFMAB）的结果
2. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma [J] . Journal of Clinical Oncology . 2012,第36期

机译：CD20 +弥漫性大B细胞淋巴瘤复发患者自体干细胞移植后的利妥昔单抗维持治疗：复发性侵袭性淋巴瘤合作试验的最终分析
3. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma [J] . Journal of Clinical Oncology . 2012,第36期

机译：CD20 +弥漫性大B细胞淋巴瘤复发患者自体干细胞移植后的利妥昔单抗维持治疗：复发性侵袭性淋巴瘤合作试验的最终分析
4. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma [O] . Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, -1

机译：CD20 +弥漫性大B细胞淋巴瘤复发患者自体干细胞移植后的利妥昔单抗维持治疗：复发性侵袭性淋巴瘤合作试验的最终分析
7. PSY89 Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute [O] . Rule S., Briones J., Smith R., 2014

机译：Cd20 +非霍奇金淋巴瘤（Nhl）患者中Rituximab皮下（Sc）和静脉内（Iv）的PSY89偏好在随机II期研究中完成Rasq措施研究Prefmab和Mabcute

PCN219 Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma

著录项

相似文献

相关主题

期刊订阅